AstraZeneca Signs US$6 B ADC Collaboration with Daiichi Sankyo for DS-1062
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 7 (Table of Contents)
Published: 31 Jul-2020
DOI: 10.3833/pdr.v2020.i7.2552 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In their second antibody drug conjugate (ADC) partnership together, AstraZeneca has agreed to collaborate with Daiichi Sankyo to develop and commercialise its Phase I candidate DS-1062 for the treatment of solid tumours connected to the TROP2 gene, such as non-small cell lung cancer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS